OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantJH
Janus Henderson Investors
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Sep 19, 2026
Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.
Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.
The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $445M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSoufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
Participant